



US005968983A

United States Patent [19]**Kaesemeyer****[11] Patent Number: 5,968,983****[45] Date of Patent: Oct. 19, 1999****[54] METHOD AND FORMULATION FOR TREATING VASCULAR DISEASE**[75] Inventor: **Wayne H. Kaesemeyer**, Augusta, Ga.[73] Assignee: **Nitrosystems, Inc**, Augusta, Ga.[21] Appl. No.: **08/833,842**[22] Filed: **Apr. 10, 1997****Related U.S. Application Data**

[63] Continuation-in-part of application No. 08/693,882, Aug. 5, 1996, Pat. No. 5,767,160, which is a continuation-in-part of application No. 08/321,051, Oct. 5, 1994, Pat. No. 5,543,430.

[51] **Int. Cl.⁶** **A01N 37/12**[52] **U.S. Cl.** **514/564; 514/565; 514/460**[58] **Field of Search** **514/565, 460,
514/564****[56] References Cited****U.S. PATENT DOCUMENTS**

4,686,211	8/1987	Hara et al.	514/148
5,059,712	10/1991	Griffith	562/560
5,132,453	7/1992	Griffith	562/560
5,158,883	10/1992	Griffith	435/240.2
5,196,195	3/1993	Griffith	424/94.6
5,273,875	12/1993	Griffith	435/1
5,316,765	5/1994	Folkers et al.	424/94.1
5,366,738	11/1994	Rork et al.	424/473
5,428,070	6/1995	Cooke et al.	514/557
5,543,430	8/1996	Kaesemeyer	514/565

OTHER PUBLICATIONS

Morris et al., "An integrated approach to the selection of optimal salt from a new drug candidate", International Journal of Pharmaceutics (Amsterdam), 105(3), 209–217, 1994, see abstract.

Patel, J. M. et al. Nitric Oxide Exposure and Sulfhydryl Modulation Alter L-Arginine Transport in Cultured Pulmonary Artery Endothelial Cells. (Abstract Only) Free Radical Biology & Medicine. vol. 20, No. 5. p. 629. 1996.

Xia, Y. et al. Nitric Oxide Synthase Generates Superoxide and Nitric Oxide in Arginine-Depleted Cells Leading to Peroxynitrite-Mediated Cellular Injury. Proc. Natl. Acad. Sci. USA. vol. 93. pp. 6770–6774. Jun. 1996.

Jeremy, R. W. et al. Effects of Dietary L-Arginine on Atherosclerosis and Endothelium-Dependent Vasodilation in the Hypercholesterolemic Rabbit. Circulation. Vol. 94, No. 3. pp. 498–506. Aug. 1, 1996.

Block, E. R. et al. Hypoxia Inhibits L-Arginine Uptake By Pulmonary Artery Endothelial Cells. (Abstract Only) Am. J. Physiol. vol. 269. L574–L580. 1995.

Mayer, B. et al. Brain Nitric Oxide Synthase is a Biopterin- and Flavin-Containing Multi-Functional Oido-Reductase. (Abstract Only) FEBS 10045. vol. 288, No. 1,2. pp. 187–191. Aug. 1991.

Weidinger, F. F. et al. Persistent Dysfunction of Regenerated Endothelium After Balloon Angioplasty of Rabbit Iliac Artery. Circulation. vol. 81, No. 5. pp. 1667–1679. May 1990.

Chester, A. H. et al. Low Basal and Stimulated Release of Nitric Oxide in Atherosclerotic Epicardial Coronary Arteries. The Lancet. vol. 336. pp. 897–900. Oct. 13, 1990.

Albina, J. E. et al. Arginine Metabolism in Wounds. Am. J. Physiol. vol. 254. pp. E459–E467. 1988.

Cooke, J.P. et al. Antiatherogenic Effects of L-Arginine in the Hypercholesterolemic Rabbit. (Abstract Only) J. Clin. Invest. vol. 90, No. 3. pp. 1168–1172. Sep. 1992.

Nakamura, Y. et al. Pravastatin Reduces Restenosis After Coronary Angioplasty of High Grade Stenotic Lesions: Results of SHIPS (SHIga Pravastatin Study). (Abstract Only). Cardiovasc. Drugs. Ther., vol. 10, No. 4, pp. 475–483. 1996.

Pohl, U. et al. Effects of LDL on Intracellular Free Calcium and Nitric Oxide-Dependent cGMP Formation on Porcine Endothelial Cells. (Abstract only) Atherosclerosis. vol. 117. pp. 169–178. 1995.

Delicostantinos, G. et al. Modulation of Particulate Nitric Oxide Synthase Activity and Peroxynitrate Synthesis in Cholesterol Enriched Endothelial Cell Membranes. (Abstract Only) Biochem. Pharm. vol. 49. No. 11. pp. 1589–1600. 1995.

Galle, J. et al. Effect of HDL and Atherogenic Lipoproteins on Formation of O₂ and Renin Release in Juxtaglomerular Cells. (Abstract Only) Kidney International. vol. 51. pp. 253–260. 1997.

Bult, H. Nitric Oxide and Atherosclerosis: Possible Implications for Therapy. (Abstract only) Molecular Medicine Today. p. 510. Dec. 1996.

Crouse III, J.R. et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). (Abstract only) Am. J. Cardiol. vol. 75. pp. 455–459. 1995.

Aji, W. et al. L-Arginine Prevents Xanthoma Development and Inhibits Atherosclerosis in LDL Receptor Knockout Mice. (Abstract only) Circulation. vol. 95. pp. 430–437. 1997.

Cooke, J. P. et al. Arginine: A new Therapy for Atherosclerosis?. Circulation. vol. 95. pp. 311–312. 1997.

Boger, R. H. et al. The L-Arginine Nitric Oxide Pathway: Role in Atherosclerosis and Therapeutic Implications. (First page only) Atherosclerosis. vol. 127. pp. 1–11. 1996.

Jay, M.T. et al. Modulation of Vascular Tone By Low Density Lipoproteins. Effects on L-Arginine Transport and Nitric Oxide Synthesis. Experimental Physiology. vol. 82. pp. 349–360. 1997.

Muramatsu, J. et al. Hemodynamic Changes Associated with Reduction in Total Cholesterol By Treatment with the HMG-CoA Reductase Inhibitor Pravastatin. Atherosclerosis. vol. 130. pp. 179–182. 1997.

(List continued on next page.)

Primary Examiner—Dwayne C. Jones
Attorney, Agent, or Firm—Reed Smith Shaw McClay LLP;
 Raymond A. Miller

[57]

ABSTRACT

A therapeutic mixture comprised of L-arginine and inhibitors of Hmg—CoA-Reductase is disclosed for the treatment of diseases related to endothelial dysfunction, wherein the endothelial dysfunction is relieved by stimulating the constitutive form of nitric oxide synthase (cNOS) to produce native nitric oxide (NO).